Clascoterone vs Finasteride
FDA Approved vs FDA Approved
synergistic Researched · 95% Clascoterone and finasteride address androgen-driven hair loss through complementary mechanisms. Finasteride inhibits 5-alpha reductase to reduce systemic DHT production, while clascoterone blocks remaining androgens from activating the receptor at the follicle. This dual approach targets both the ligand supply and the receptor activation, potentially providing greater efficacy than either agent alone.
Molecular Data
Clascoterone Finasteride
Weight 388.54 Da 372.54 Da
Half-life Short topical (local action; rapidly metabolized to cortexolone) 6-8 hours (DHT suppression persists ~24 hours)
Type Steroidal androgen receptor inhibitor Synthetic 4-azasteroid compound
Key Benefits
Clascoterone
01 First-in-class topical androgen receptor inhibitor with FDA approval for acne
02 Blocks androgen action locally at the sebaceous gland and hair follicle without systemic hormonal effects
03 Suitable for both men and women, unlike systemic anti-androgens
04 Rapidly metabolized to inactive cortexolone, limiting systemic exposure
05 No clinically meaningful effects on systemic testosterone, DHT, or gonadotropin levels
06 Addresses the root androgen-driven pathology of both acne and androgenetic alopecia
Finasteride
01 Reduces scalp DHT by approximately 66% at 1mg daily
02 Slows or stops hair loss progression in roughly 90% of men
03 Produces visible hair regrowth in approximately 48% of men within 1-2 years
04 FDA-approved with over 25 years of clinical use and long-term safety data
05 Convenient once-daily oral dosing with no injections required
06 Well-characterized side effect profile with low incidence of adverse events
07 Can be combined with minoxidil for enhanced efficacy
Side Effects
Clascoterone
Application site irritation, redness, or dryness
Pruritus (itching) at the application site
Contact dermatitis in sensitive individuals
Finasteride
Decreased libido (reported in 1.8% of men in clinical trials vs 1.3% placebo)
Erectile dysfunction (reported in 1.3% vs 0.7% placebo)
Decreased ejaculate volume (reported in 0.8% vs 0.4% placebo)
Contraindications
Known hypersensitivity to clascoterone or any component of the formulation
Women who are pregnant or planning to become pregnant (anti-androgens carry theoretical teratogenic risk)
Women who are breastfeeding (safety not established)
Active skin infections at the intended application site
Women who are pregnant or may become pregnant (finasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling crushed tablets poses a risk)
Women who are breastfeeding
Known hypersensitivity to finasteride or any component of the formulation
Severe hepatic impairment (finasteride is metabolized by the liver)
Pediatric patients (not indicated for use in children)
Research Evidence
Clascoterone Finasteride
Status FDA Approved FDA Approved
References 4 studies 5 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.